参考文献/References:
[1] 齐今吾.内分泌疾病相关高血糖和(或)糖尿病//刘新民,齐今吾,杨晓凤,等.内分泌疾病:鉴别珍断与治疗学.北京:人民军医出版社,2009:358.
[2] Bhattacharyya A, Wiles PC. Diabetic ketocidosis precipitated by thyrotoxicosis. Postgrad Med J, 1999,75(833):291-292.
[3] Moller N, Nielsen S, Nyholm B, et al. Glucose turnover, fuel oxidation and forearm substrate exchange in patients with thyrotoxicosis before and after medical treatment. Clin Endocrinol (Oxf), 1996,44(4):453-459.
[4] Loeb JN. Metabolic changes in thyrotoxicosis//Braverman LE, Utiger RD. Werner and Ingbar’s the thyroid. Philadelphi a:Lippincott-Raven, 1996:687-693.
[5] Gasińska T, Nowak S, Beldzik A, et al. Levels of free fatty acids in plasma, tissue utilization coefficient of glucose K and insulin secretion following intravenous glucose load in hyper-thyroid patients treated with propranolol or acebutolol. Pol Tyg Lek, 1994, 49(1-3):7-10.
[6] Mokuno T, Uchimura K, Hayashi R, et al. Glucose transporter 2 concentrations in hyper-and hypothyroid rat livers. J Endocrinol, 1999.160(2):285-289.
[7] Bech K, Damsbo P, Eldrup E. et al. Beta-cell function and glucose and lipidoxidation in Graves’ disease. Clin Endocrinol (oxf), 1996, 44(1):59-66.
[8] Yki-Järvinen H. Toxicity of hyperglycaemia in type 2 diabetes. Diabetes Metab Rev, 1998, 14(Suppl 1):S45-S50.
[9] Stumvoll M, Fritsche A, Stefan N, et al. Evidence against a ratelimiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunctioa J Clin Endocrinol Metah, 2001, 86(3); 1235-1239.
[10] Reder ME, Schwartz RS, Prigeon RL. et al. Reduced pancreatic B cell compensation to the insulin resistance of aging:impact on proinsulin and insulin levels. J Clin Endocrinol Metab, 2000,85(6):2275-2280.
[11] Larsson H, Ahrén B. Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. J Clin Endocrinol Metab, 1999, 84(6); 2068-2074.
[12] Eizirik DU Darville ML Beta-cell apoptosis and defense mechanisms:lessons from type 1 diabetes. Diabetes, 2001, 50(Suppl 1):S64-S69.
[13] Jörns A, Tiedge M, Lenzen S. Thyroxine induces pancreatic beta cell apoptosis in rats. Dialjetoiogia, 2002,45(6):851-855.
[14] Yavuz DG, Ytiksel M, Deyneli O, et al. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goiter patients. Clin Endocrinol, 2004, 61(4):515-521.
[15] Riis AL, Gravholt CH, Djurhuns CB, et al-Elevated regional lipolysis in hyperthyroidism. J Clin Endocrinol Matab, 2002, 87(10):4747-4753.
[16] Dimitriadis G, Milrou P, Lambadiari V, et al. Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism. J Clin Endocrin Metab, 2006,91(3):1112-1118.
[17] Shimabukuro M, Zhou YT, Levi M, et al. Fatty acid induced betacell apoptosis:a link between obesity and diabetes. Proc Natl Acad Sci USA, 1998,95⑶:2498-2502.
[18] Heimberg H, Heremans Y, Jobin C, et al. Inhibition of cytokine induced NF-kappa B activation by adenovirus mediated expression of a NF-kappaB super-repressor prevent beta-cell apoptosis. Diabetes, 2001, 50(10):2219-2224.
[19] lossa S, Lionetti L, Mollica MP, et al. Fat balance and serum leptin concentrations in normal, hypothyroid, and hyperthyroid rats. Int J Obes Relat Metab Disord, 2001,25⑶:417-425.
[20] Roubsanthisuk W, Watanakejom P, Tunlakit M, et al. Hyperthyroidism induces glucose intolerance by lowering both insulin secretion and peripheral insulin sensitivity. J Med Assoc Thai, 2006, 89(Suppl 5):S133-S140.
[21] Jenkins RC, Valcavi R, Zini M, et al. Association of elevated insulin-like growth factor binding protein-1 with insulin resistance in hyperthyroidism. Clin Endocrinol (Oxf), 2000, 52(2):187-195.
[22] Fukuchi M, Shimabukuro M. Shimajiri Y, et al. Evidence for a deficient pancreatic beta-cell response in a rat model of hyperthyroidism. Life Sci, 2002, 71(9):1059-1070.
[23] Douglas RS, Gianoukakis AG, Kamat S, et al. Aberrant expression of the insulin-like crowth factor-1 receptor by T cells from patients with Graves’ disease may carry functional consequences for disease pathogenesis. J Immunol, 2007,178(5):3281-3287.
[24] Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves’disease aberrantly express the IGF-1 receptor implicaticms (or disease pathogenesis. J Immunol, 2008, 181(8):5768-5774.
[25] Maugendre D, Sonnet E, Denien C, et al. Combined analysis of long-lerm anti-beta-cell humoral reactivity in type 1 diabdes with and without thyroid disease. Diabetes Metab, 1999, 25(1):28-33.
[26] Wu TJ, Huang SM, Taylor RL, et al. Abnormal proinsulin levels in thyroid dysfunction measured by a sensitive proinsulin immuno-chemiluminoassay.Ann Clin Lab Sci,1998.28(2):82-87
[27] Hwang IK, Kim IY, Kim YN, et al. Effects of methiimazole on the onset of type 2 diabetes in leptin receptor-deficient rats. J Vet Med Sci, 2009, 71(3):275-280.
[28] 闫瑞红,杨天正,周振虎,等.131I治疗Graven病合并糖尿病的疗效分析.中华核医学杂志,2008,28(5):351.
[29] 赵德善,孔繁振,司宏伟,等.儿童和育少年甲状腺功能亢进症的叫治疗.中华内分泌代谢杂志,2006,22(6):566-568.
[30] 廖二元,超楚生.内分泌学//戴如春,廖二元.继发性糖尿病与遗传性糖尿病.北京:人民卫生出版社,2003:1620.
相似文献/References:
[1]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[2]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[3]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[4]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[5]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[6]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
[7]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[8]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[9]张建媛,缪蔚冰.电化学发光法与放射性受体分析法检测促甲状腺激素受体抗体的对比研究[J].国际放射医学核医学杂志,2012,36(1):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
ZHANG Jian-yuan,MIAO Wei-bing.Comparative study between electrochemiluminescence immunoassay and radioactive receptor assay in measurement of serum thyrotropin receptor antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
[10]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[13]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[14]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[15]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[16]袁卫红,张怡,罗志航.内分泌性眼病患者外周血中白细胞介素6和胰岛素样生长因子1水平变化的研究[J].国际放射医学核医学杂志,2008,32(3):167.
YUAN Wei-hong,ZHANG Yi,LUO Zhi-hang.The investigation of cytokine level in peripheral blood of patients with thyroid eye disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):167.
[17]覃伟武.131Ⅰ治疗非Graves’甲状腺功能亢进及非毒性甲状腺肿后诱发Graves’病[J].国际放射医学核医学杂志,2006,30(6):325.
QIN Wei-wu.Induction of Graves’ disease in patients with non-autoimmune hyperthyroidism or nontoxic goiter after radioiodine treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):325.
[18]赵炎,王俊起,沈婕.Graves病的131I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析[J].国际放射医学核医学杂志,2017,41(6):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]
Zhao Yan,Wang Junqi,Shen Jie.131I therapy versus antithyroid drugs in Graves’ disease:a meta-analysis of randomized controlled trials[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(3):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]